ASPIRA PATHLAB & DIAGNOSTICS | KIMS | ASPIRA PATHLAB & DIAGNOSTICS / KIMS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -13.1 | 43.9 | - | View Chart |
P/BV | x | 2.5 | 9.6 | 26.1% | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
ASPIRA PATHLAB & DIAGNOSTICS KIMS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASPIRA PATHLAB & DIAGNOSTICS Mar-23 |
KIMS Mar-23 |
ASPIRA PATHLAB & DIAGNOSTICS / KIMS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 75 | 1,669 | 4.5% | |
Low | Rs | 26 | 1,116 | 2.3% | |
Sales per share (Unadj.) | Rs | 14.0 | 274.6 | 5.1% | |
Earnings per share (Unadj.) | Rs | -0.1 | 45.7 | -0.2% | |
Cash flow per share (Unadj.) | Rs | 1.5 | 61.9 | 2.4% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 12.4 | 208.6 | 5.9% | |
Shares outstanding (eoy) | m | 10.29 | 80.03 | 12.9% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.6 | 5.1 | 70.7% | |
Avg P/E ratio | x | -583.7 | 30.5 | -1,916.0% | |
P/CF ratio (eoy) | x | 34.6 | 22.5 | 153.7% | |
Price / Book Value ratio | x | 4.1 | 6.7 | 60.9% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 518 | 111,435 | 0.5% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 56 | 3,464 | 1.6% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 145 | 21,977 | 0.7% | |
Other income | Rs m | 3 | 374 | 0.9% | |
Total revenues | Rs m | 148 | 22,351 | 0.7% | |
Gross profit | Rs m | 16 | 6,140 | 0.3% | |
Depreciation | Rs m | 16 | 1,293 | 1.2% | |
Interest | Rs m | 4 | 373 | 1.1% | |
Profit before tax | Rs m | -1 | 4,849 | -0.0% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 0 | 1,191 | 0.0% | |
Profit after tax | Rs m | -1 | 3,658 | -0.0% | |
Gross profit margin | % | 11.0 | 27.9 | 39.4% | |
Effective tax rate | % | 0 | 24.6 | -0.0% | |
Net profit margin | % | -0.6 | 16.6 | -3.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 59 | 4,776 | 1.2% | |
Current liabilities | Rs m | 16 | 2,965 | 0.5% | |
Net working cap to sales | % | 29.5 | 8.2 | 358.4% | |
Current ratio | x | 3.7 | 1.6 | 229.3% | |
Inventory Days | Days | 88 | 41 | 213.0% | |
Debtors Days | Days | 590 | 42 | 1,407.0% | |
Net fixed assets | Rs m | 115 | 24,235 | 0.5% | |
Share capital | Rs m | 103 | 800 | 12.9% | |
"Free" reserves | Rs m | 25 | 15,895 | 0.2% | |
Net worth | Rs m | 128 | 16,695 | 0.8% | |
Long term debt | Rs m | 10 | 4,974 | 0.2% | |
Total assets | Rs m | 173 | 29,011 | 0.6% | |
Interest coverage | x | 0.8 | 14.0 | 5.6% | |
Debt to equity ratio | x | 0.1 | 0.3 | 25.3% | |
Sales to assets ratio | x | 0.8 | 0.8 | 110.0% | |
Return on assets | % | 1.9 | 13.9 | 13.6% | |
Return on equity | % | -0.7 | 21.9 | -3.2% | |
Return on capital | % | 2.4 | 24.1 | 9.9% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 0 | 109 | 0.0% | |
Fx outflow | Rs m | 0 | 14 | 0.0% | |
Net fx | Rs m | 0 | 95 | 0.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 0 | 4,321 | -0.0% | |
From Investments | Rs m | 2 | -6,156 | -0.0% | |
From Financial Activity | Rs m | -9 | 883 | -1.1% | |
Net Cashflow | Rs m | -8 | 360 | -2.2% |
Indian Promoters | % | 18.7 | 38.8 | 48.2% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 49.9 | - | |
FIIs | % | 0.0 | 16.7 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 81.3 | 61.2 | 132.9% | |
Shareholders | 1,512 | 69,092 | 2.2% | ||
Pledged promoter(s) holding | % | 0.0 | 16.1 | - |
Compare ASPIRA PATHLAB & DIAGNOSTICS With: APOLLO HOSPITALS DR. LAL PATHLABS METROPOLIS HEALTHCARE NARAYANA HRUDAYALAYA THYROCARE TECHNOLOGIES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | ASPIRA PATHLAB & DIAGNOSTICS | KIMS | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -5.02% | -1.79% | 0.31% |
1-Month | -6.11% | -3.77% | 0.08% |
1-Year | -6.45% | 33.02% | 54.11% |
3-Year CAGR | 1.07% | 28.20% | 14.46% |
5-Year CAGR | -2.37% | 16.08% | 20.04% |
* Compound Annual Growth Rate
Here are more details on the ASPIRA PATHLAB & DIAGNOSTICS share price and the KIMS share price.
Moving on to shareholding structures...
The promoters of ASPIRA PATHLAB & DIAGNOSTICS hold a 18.7% stake in the company. In case of KIMS the stake stands at 38.8%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of ASPIRA PATHLAB & DIAGNOSTICS and the shareholding pattern of KIMS.
Finally, a word on dividends...
In the most recent financial year, ASPIRA PATHLAB & DIAGNOSTICS paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
KIMS paid Rs 0.0, and its dividend payout ratio stood at 0.0%.
You may visit here to review the dividend history of ASPIRA PATHLAB & DIAGNOSTICS , and the dividend history of KIMS.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on positive note, Indian share markets continued the momentum as the session progressed and ended higher.